Inhibiting SCD Expression by IGF1R during Lorlatinib Therapy Sensitizes Melanoma to Ferroptosis
The authors used a drug synergy screen that combined a ferroptosis inducer, RSL3, with 240 anti-tumor drugs from the FDA-approved drug library and identified lorlatinib to synergize with RSL3 in melanoma cells.
[89bio, Inc.] 89bio, Inc. announced positive topline data from the Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with NASH. In the study, both the 44mg Q2W and 30mg QW doses met, with high statistical significance.
[Communications Biology] The expression of myocardial infarction-associated transcript (MIAT) was up-regulated during liver fibrosis. Silencing MIAT led to the suppression of hepatic stellate cell proliferation and collagen expression.